National Asset Management Inc. boosted its holdings in shares of Stryker Co. (NYSE:SYK) by 5.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,126 shares of the medical technology company’s stock after buying an additional 909 shares during the period. National Asset Management Inc.’s holdings in Stryker were worth $3,520,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the business. Integrated Advisors Network LLC raised its holdings in shares of Stryker by 3.5% in the 3rd quarter. Integrated Advisors Network LLC now owns 2,746 shares of the medical technology company’s stock worth $572,000 after acquiring an additional 93 shares during the last quarter. Marble Harbor Investment Counsel LLC increased its position in shares of Stryker by 0.5% during the third quarter. Marble Harbor Investment Counsel LLC now owns 26,312 shares of the medical technology company’s stock valued at $5,483,000 after acquiring an additional 129 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in Stryker by 11.2% during the third quarter. Victory Capital Management Inc. now owns 160,832 shares of the medical technology company’s stock worth $33,513,000 after acquiring an additional 16,258 shares during the period. Courier Capital LLC boosted its position in Stryker by 48.9% in the third quarter. Courier Capital LLC now owns 1,748 shares of the medical technology company’s stock worth $373,000 after purchasing an additional 574 shares during the last quarter. Finally, Valmark Advisers Inc. grew its stake in Stryker by 14.2% in the 3rd quarter. Valmark Advisers Inc. now owns 1,284 shares of the medical technology company’s stock valued at $268,000 after purchasing an additional 160 shares during the period. 71.02% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts recently weighed in on SYK shares. TheStreet raised shares of Stryker from a “c+” rating to a “b+” rating in a report on Thursday, October 29th. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a research report on Friday, July 31st. Raymond James lifted their price target on shares of Stryker from $220.00 to $240.00 and gave the stock an “outperform” rating in a report on Monday, October 12th. Smith Barney Citigroup upped their price objective on Stryker from $232.00 to $240.00 in a research note on Friday, October 30th. Finally, Robert W. Baird boosted their target price on Stryker from $243.00 to $258.00 and gave the company an “outperform” rating in a research note on Thursday, November 12th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $220.23.
NYSE:SYK traded down $5.66 during mid-day trading on Tuesday, reaching $230.12. The stock had a trading volume of 10,630 shares, compared to its average volume of 1,694,754. The stock has a market capitalization of $88.60 billion, a P/E ratio of 56.00, a P/E/G ratio of 3.71 and a beta of 0.78. The firm has a 50 day moving average price of $216.57 and a two-hundred day moving average price of $197.84. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.12 and a current ratio of 2.91. Stryker Co. has a one year low of $124.54 and a one year high of $241.53.
Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 29th. The medical technology company reported $2.14 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.40 by $0.74. Stryker had a net margin of 11.38% and a return on equity of 20.53%. The company had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.41 billion. During the same quarter in the prior year, the company earned $1.91 EPS. The firm’s revenue was up 4.2% on a year-over-year basis. Research analysts forecast that Stryker Co. will post 6.33 earnings per share for the current year.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices that are used in various medical specialties.
Further Reading: What is a dead cat bounce?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.